Phentolamine (Zona's Vasomax) main side effect is hypotension (we discussed it here before)tachycardia (increases with time of use) and arrhytmias, shock, excitation, headache, sweating,visual disturbances, nausea, vomiting ,diarrhea, hypoglicemia, in heavy doses it can trigger massive gastric bleeding (like cousin tolazoline).
Besides, phentolamine oral absorption is ERRATIC.
We agreed before that for phentolamine to be approved the FDA will have to look the other way and forget about the side effects. But it is already approved for many indications, it could be difficult for the FDA not to approve it ( if trials are very good in the safety part). Seldane is still out, Redux is still out and the combination phen-fen is banned,but both drugs are still out there. Can they ask for limited use to young, non compromise (cardiac,diabetes) patients? yes, once out then physicians will use it. (remember phen-fen and redux)even in many non approved cases.
Stock wise my worry is the ability of Vivus to swing wildly (and my margin account with it)even with non real news. If the day comes and Zona is approved I will like a crystal ball so I am out of margin that day. If we count with the FDA and logic (patient safety) even the trials are not supposed to be approved and they are (I do not mean FDA approved this I do not know if Zona file for an IND applicaton, but at least there must be an ethical committe somewhere who did approved it)
A big company to adquire Vivus will have to really do a heavy muscle work out. I do not think the management will give away their 14 million shares for little money, unless they are very impatient, cause they know better than anybody out here that the stock will be $200, like somebody predicted.
For side effects I use my regular PDR and Pharmacology books. The internet for abstracts and research.
Maybe they can adquire HVSF (ggg) or Senetek (to help with the London approval, ggg). Just wild speculation. |
